ZVRA Financials

Income Statement
MetricQ2 2026Q2 2026Q1 2026Q1 2026Q4 2025
Revenue
39.7M
+0.0%
39.7M
+9.5%
36.2M
+0.0%
36.2M
+6.1%
34.1M
Cost of Revenue
1.5M
+0.0%
1.5M
-19.6%
1.9M
+0.0%
1.9M
+24.8%
1.5M
Gross Profit
38.1M
+0.0%
38.1M
+11.1%
34.3M
+0.0%
34.3M
+5.3%
32.6M
Operating Expenses
21.4M
+0.0%
21.4M
-16.2%
25.5M
+0.0%
25.5M
+9.5%
23.3M
R&D
4.5M
+0.0%
4.5M
+2.1%
4.4M
+0.0%
4.4M
+67.6%
2.6M
SG&A
16.6M
+0.0%
16.6M
-20.3%
20.8M
+0.0%
20.8M
+2.1%
20.4M
Operating Income
16.8M
+0.0%
16.8M
+90.0%
8.8M
+0.0%
8.8M
-5.2%
9.3M
EBITDA
17.1M
+0.0%
17.1M
+86.3%
9.2M
+0.0%
9.2M
+118.8%
-49033000
Net Income
8.8M
+0.0%
8.8M
-76.9%
37.9M
+0.0%
37.9M
+211.5%
12.2M
EPS (Basic)
$0.14
+0.0%
$0.14
-77.4%
$0.62
+0.0%
$0.62
+181.8%
$0.22
EPS (Diluted)
$0.14
+0.0%
$0.14
-76.7%
$0.60
+0.0%
$0.60
+215.8%
$0.19
Shares (Diluted)
61.3M
+0.0%
61.3M
+1.8%
60.2M
+0.0%
60.2M
-3.9%
62.7M
Zevra Therapeutics (ZVRA) โ€” Financials